Cognitive behavioral therapy for psychosis (CBTp): NICE-recommended adjunct
Assertive Community Treatment: reduces hospitalizations in high-risk patients
Coordinated specialty care for first-episode psychosis: improves functional outcomes
Substance use comorbidity
Comorbid substance use disorders in approximately 50% of patients
Cannabis and stimulant use: 3-fold increased relapse risk
Integrated dual-diagnosis treatment superior to sequential treatment
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for schizophrenia exacerbation
Your diagnosis
You were evaluated for a worsening of your schizophrenia symptoms
Tests were done to make sure there was no other medical cause for your symptoms
Your medications
Take all medications exactly as prescribed
Do not stop or change your antipsychotic medication without talking to your doctor
Missing even a few doses greatly increases your risk of symptom return
If you are having side effects, call your doctor before stopping the medication
Follow-up appointments
See your psychiatrist or mental health provider within 1 week
See your family doctor within 2 to 4 weeks for blood tests and weight check
Keep all scheduled appointments
Things to avoid
Do not use cannabis, cocaine, methamphetamine, or other street drugs
These substances can cause your symptoms to return quickly
Avoid alcohol
Warning signs to watch for
Return to the emergency department immediately if you develop
Thoughts of harming yourself or others
Voices or beliefs that are getting worse or feeling unsafe
Unable to eat, drink, or take care of yourself
Fever with muscle stiffness or confusion: this may be a serious medication side effect
Uncontrolled shaking, muscle spasms, or inability to sit still
Severe restlessness or pacing that you cannot control
Recovery expectations
Agitation and severe distress can improve within hours of treatment
Full improvement in thinking and perception usually takes 2 to 6 weeks
Continue taking medication even when you feel better
Support resources
Tell a trusted family member or friend about your diagnosis and medications
Crisis line: 988 Suicide and Crisis Lifeline (call or text 988)
If in danger, call 911
References
Guidelines and key sources
Clinical guidelines and policy statements
ACEP Clinical Policy: Diagnosis and Management of the Adult Psychiatric Patient in the ED
Nazarian DJ et al. Annals of Emergency Medicine. 2017
Level B recommendation: IM haloperidol plus lorazepam or IM olanzapine for acute agitation
Level B recommendation: droperidol effective for acute agitation
VA/DoD Clinical Practice Guideline for Management of First-Episode Psychosis and Schizophrenia (2023)
Arias-Reynoso et al. Department of Veterans Affairs 2023
Comprehensive guidance on relapse prevention, LAIs, metabolic monitoring, psychosocial care
DSM-5-TR Schizophrenia Criteria
American Psychiatric Association 2022
Landmark studies and reviews
Key evidence sources
Marco CA, Vaughan J. Emergency Management of Agitation in Schizophrenia
American Journal of Emergency Medicine 2005
Foundational ED agitation management protocols
Marder SR, Cannon TD. Schizophrenia. NEJM 2019
Comprehensive pathophysiology and treatment review
McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia: An Overview. JAMA Psychiatry 2020
Epidemiology, biomarkers, and treatment evidence synthesis
Alvarez-Jimenez M et al. Risk Factors for Relapse Following First Episode Psychosis
Schizophrenia Research 2012
Meta-analysis identifying nonadherence and substance use as top relapse predictors
Brandt L et al. Predicting Psychotic Relapse. Lancet Psychiatry 2023
LAI antipsychotics reduce relapse HR 0.53 versus oral antipsychotics
Schneider-Thoma J et al. Comparative Efficacy of Antidopaminergic and Muscarinic Antipsychotics
Lancet 2026: network meta-analysis of randomised controlled trials
Siafis S et al. Relapse in Clinically Stable Adults With Schizophrenia. Lancet Psychiatry 2024
Evidence-based relapse criteria by equipercentile linking
Ostinelli EG et al. Aripiprazole IM for Psychosis-Induced Agitation. Cochrane 2018
Efficacy of aripiprazole IM for rapid tranquillisation
Du W et al. QTc Prolongation in Patients With Schizophrenia on Antipsychotics
Journal of Psychopharmacology 2023: prevalence approximately 4%
Hua LL. Collaborative Care in Identification and Management of Psychosis in Adolescents
Pediatrics 2021: coordinated specialty care model
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.